Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the beta-lactam antibiotic, ceftriaxone, in mice

Basit Öğe Kaydı
dc.authoridGunduz, Ozgur/0000-0002-2470-3021
dc.authoridUlugol, Ahmet/0000-0003-4643-1124
dc.authoridOltulu, Cagatay/0000-0002-6051-3479
dc.authorwosidGÜNDÜZ, Özgür/AAH-8717-2019
dc.authorwosidGunduz, Ozgur/A-2351-2016
dc.authorwosidUlugol, Ahmet/V-9665-2019
dc.authorwosidOltulu, Cagatay/V-1823-2018
dc.contributor.authorGunduz, Ozgur
dc.contributor.authorOltulu, Cagatay
dc.contributor.authorUlugol, Ahmet
dc.date.accessioned2024-06-12T10:55:37Z
dc.date.available2024-06-12T10:55:37Z
dc.date.issued2011
dc.departmentTrakya Üniversitesien_US
dc.description.abstractRecently, it has been indicated that beta lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Furthermore, these antibiotics have been shown to prevent the development of tolerance and dependence to opioids. Since cannabinoid tolerance is known to be similar to opioids, our purpose was to examine the effect of ceftriaxone on the development of tolerance to WIN 55,212-2, a cannabinoid agonist. The tail flick test, a rectal thermometer, and the ring test were used for evaluating the degree of tolerance to the analgesic, hypothermic, and cataleptic effects of WIN 55,212-2, respectively. Within one week, animals became completely tolerant to analgesic. hypothermic and cataleptic effects of WIN 55,212-2 (6 mg/kg). Ceftriaxone, with its higher doses (100-200 mg/kg), attenuated the development of tolerance to the analgesic and hypothermic effects of WIN 55,212-2, but had no effect on its cataleptic action. Dihydrokainic acid (10 mg/kg), a GLT-1 transporter inhibitor, prevented this effect of ceftriaxone. Our results suggest that repeated treatment with ceftriaxone prevents the development of tolerance to the analgesic and hypothermic effects of cannabinoids, and GLT-1 activation appears to play a key role in this preventive effect of beta-lactam antibiotics. (C) 2011 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.pbb.2011.04.012
dc.identifier.endpage103en_US
dc.identifier.issn0091-3057
dc.identifier.issue1en_US
dc.identifier.pmid21536061en_US
dc.identifier.scopus2-s2.0-79955728789en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage100en_US
dc.identifier.urihttps://doi.org/10.1016/j.pbb.2011.04.012
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19488
dc.identifier.volume99en_US
dc.identifier.wosWOS:000291909900015en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofPharmacology Biochemistry And Behavioren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCannabinoiden_US
dc.subjectToleranceen_US
dc.subjectCeftriaxoneen_US
dc.subjectGLT-1en_US
dc.subjectDihydrokainic Aciden_US
dc.subjectNitric-Oxideen_US
dc.subjectExpressionen_US
dc.subjectPainen_US
dc.subjectDependenceen_US
dc.subjectReceptorsen_US
dc.subjectAnalgesicsen_US
dc.subjectMorphineen_US
dc.subjectBrainen_US
dc.titleRole of GLT-1 transporter activation in prevention of cannabinoid tolerance by the beta-lactam antibiotic, ceftriaxone, in miceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu